A last-minute provision, passed with budget legislation, may give Massachusetts a state-run bulk pharmaceutical purchasing program.
A last-minute provision, passed with budget legislation, may give Massachusetts a state-run bulk pharmaceutical purchasing program. If implemented, the state-sponsored program would be run by a third party and would negotiate discounts with pharmaceutical companies for underinsured members of the state's 1.5 million citizens.
Pharmaceutical companies have reacted harshly to the program, which they say is vague and ill-conceived. "[The Massachusetts state government is] going to set up a government-controlled, bulk-purchasing program for the Commonwealth of Massachusetts for 'all the underinsured folks in the state.' Well, what does that mean?" asked Jeff Trewhitt, spokesman for the Washington-based Pharmaceutical Research and Manufacturers of America. "Are they talking about half the state, a fourth [of] the state, or what? There is no precise definition there."
According to PhRMA, the state's Medicaid and senior pharmacy programs are already in place to serve the senior population. By taking seniors out of those established programs and enrolling them in the new program, Massachusetts would sacrifice $73 million worth of rebates through Medicaid and $2 million in rebates through the senior pharmacy program.
Despite the fact that it would be run by a third party - most likely former Rep. Joseph Kennedy's not-for-profit company, Citizens Energy Corp. - the government-controlled aspect of the program is what has PhRMA worried the most. "If you look at bulk purchasing programs in other industries, you see a tendency to put price controls into place," said Trewhitt. "There is that strong potential here because this is going to be a state-run program. And [whenever] any government entity gets into a program where, all of a sudden, the cost is greater than expected, the inclination is to slap on price controls or engage in rationing. Neither option is very attractive." PR
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.